ArticleJACC. Case reports2025
Evolution of Inflammation-Associated Coronary Artery Disease on Immunosuppressive Therapy.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Selected Vascular, Inflammatory, and Lipid Parameters in Patients with Selected Keratinization Disorders: Preliminary Data from a Retrospective Observational Study.Journal of clinical medicine · 2026Article
- Inflammation-associated rapidly progressive coronary artery disease: a case report.European heart journal. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammation plays important roles in the pathogenesis of coronary artery disease (CAD). CASE SUMMARY: This case involves a middle-aged woman with few risk factors for atherosclerotic CAD but elevated erythrocyte sedimentation rate and high-sensitivity C-reactive protein. The patient developed progressive coronary de novo stenosis and restenosis despite optimal revascularization and strict secondary prevention. Immunosuppressive therapy was administered without further revascularization, which was associated with no further progression but even regression of the coronary lesions. DISCUSSION: We propose to use inflammation-associated CAD (I-CAD) to define the disease entity of this patient. This case highlights the importance of inflammation in the pathogenesis of and use of immunosuppressive therapy in the treatment of patients with I-CAD. TAKE-HOME MESSAGES: I-CAD should be considered in patients presenting with progressive CAD despite optimal standard treatment, who have few risk factors for atherosclerosis but manifestations of inflammation. Immunosuppressive therapy might be crucial to control the progression of I-CAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.